DSG1-AS1: A Potential Drug Target and Biomarker (G101927718)

Target Name: DSG1-AS1

NCBI ID: G101927718

DSG1-AS1

Other Name(s): DSG1-AS1 variant 1 | DSG1 antisense RNA 1

DSG1-AS1: A Potential Drug Target and Biomarker

DSG1-AS1 (DSG1-AS1 variant 1) is a protein that is expressed in the brain and has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. DSG1-AS1 is a transmembrane protein that is composed of four structural domains: a catalytic domain, a transmembrane domain, an intracellular domain, and a C-terminal domain.

The catalytic domain is responsible for the protein's catalytic activity, which is essential for its function in intracellular signaling. The transmembrane domain is responsible for the protein's ability to interact with intracellular signaling molecules. The intracellular domain is responsible for the protein's ability to interact with the cytoskeleton and other cellular structures. The C-terminal domain is a variable region that is involved in the protein's stability and localization to the cytoskeleton.

DSG1-AS1 has been shown to play a role in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. It is expressed in the brain and has been shown to localize to specific cellular structures, including the endoplasmic reticulum (ER) and the axon.

DSG1-AS1 has also been shown to interact with various intracellular signaling molecules, including microtubules, actinin, and tyrosine kinase. It has been shown to play a role in intracellular signaling pathways, including the regulation of neurotransmitter release, cell survival, and inflammation.

DSG1-AS1 has also been shown to be a potential biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. It has been shown to be decreased in individuals with Alzheimer's disease and to be increased in individuals with Parkinson's disease.

The potential drug target for DSG1-AS1 is the regulation of its intracellular signaling activity and its localization to specific cellular structures in the brain. This can be achieved by inhibiting the activity of microtubules, which are responsible for the transport of intracellular signaling molecules, or by blocking the localization of DSG1-AS1 to specific cellular structures in the brain.

Conclusion

DSG1-AS1 is a protein that has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Its function in intracellular signaling and its localization to specific cellular structures in the brain make it an attractive target for drug development. Further research is needed to fully understand the role of DSG1-AS1 in neurological and psychiatric disorders and to develop effective treatments.

Protein Name: DSG1 Antisense RNA 1

The "DSG1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DSG1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets